TORONTO, June 10, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021. “We are well-positioned, both financially and operationally, to execute on our…


Previous articleMYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs
Next articleEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US